Viewing Study NCT06759558


Ignite Creation Date: 2025-12-25 @ 12:06 AM
Ignite Modification Date: 2026-01-03 @ 7:52 PM
Study NCT ID: NCT06759558
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-15
First Post: 2024-12-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Allopregnanolone (Zuranolone) in Post-stroke Depression
Sponsor: Duke University
Organization:

Study Overview

Official Title: Allopregnanolone (Zuranolone) in Post-stroke Depression
Status: NOT_YET_RECRUITING
Status Verified Date: 2025-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ALLO in PSD
Brief Summary: The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it will aim to answer are:

* Is zuranolone safe to take by participants who have moderate to severe post-stroke depression?
* Is zuranolone well-tolerated by participants who have moderate to severe post-stroke depression?
* Does zuranolone treat moderate to severe post-stroke depression?

The study will enroll six participants. All participants will be given 50 mg of zuranolone for 14 days.

Participants will be asked to provide blood samples, complete some questionnaires including those related to mood and a cognitive assessment.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: